ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO0055

Silent Lungs, Loud Kidneys: Renal Sarcoidosis

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials

Authors

  • Abi Doumet, Amanda, UConn Health, Farmington, Connecticut, United States
  • Yamase, Herald, UConn Health, Farmington, Connecticut, United States
  • Ackley, William, UConn Health, Farmington, Connecticut, United States
Introduction

Renal sarcoidosis is rare, often occurring with extrarenal disease. Its true incidence is unknown, though autopsies reveal granulomatous interstitial nephritis in up to 23% of sarcoidosis cases. We report a case of biopsy-proven renal sarcoidosis in a patient with stable lung imaging but declining renal function.

Case Description

71 yo woman with stable mediastinal lymphadenopathy and weight loss was referred for AKI (Cr 0.8→1.8mg/dL over 8 months). Workup showed mild proteinuria, hypercalcemia, anemia, elevated 1,25-vit D, and inflammatory markers. Without pulmonary progression to justify treatment, she underwent a renal biopsy, which revealed granulomatous tubulointerstitial nephritis and nephrocalcinosis, consistent with sarcoidosis. She was started on prednisone 40mg daily with improved Cr to 1.0 at 12 wks, and normalization of calcium levels, hemoglobin, and CRP.

Discussion

Renal sarcoidosis is rare, especially without other organ involvement. As such, requiring a kidney biopsy to change management is uncommon. Classic findings include granulomatous interstitial nephritis, but non-granulomatous interstitial nephritis and nephrocalcinosis can also occur. Biopsy can aid with prognosis, as the extent of fibrosis may predict steroid response. Early treatment with steroids (0.5-1mg/kg/day) is key to preventing ESKD, but no formal guidelines exist. Our patient responded to an initial dose of 0.7mg/kg prednisone, with renal function improving near baseline in 12 weeks. However, with relapse rates of 30-40%, long-term management remains a challenge needing further research.

Digital Object Identifier (DOI)